Table 4

Univariate analyses of the MIS and other clinical variables

Variable	HR	95% CI	P value
CD14⁺HLA-DR^neg*	1.5869	1.5321 to 1.6438	<0.0001
CD14⁺PD-L1⁺*	1.5711	1.4753 to 1.6731	<0.0001
CD14⁺*	3.7135	3.3118 to 4.1640	<0.0001
CD15⁺*	1.2116	1.1853 to 1.2386	<0.0001
MIS (>0 vs 0)	8.3281	7.0773 to 9.7999	<0.0001
NLR*	1.7275	1.6127 to 1.8506	<0.0001
Tumor burden (high vs low)	2.1928	1.8942 to 2.5385	<0.0001
ANC*	1.4357	1.3575 to 1.5185	<0.0001
log(LDH)*	2.0613	1.8610 to 2.2832	<0.0001
WBC*	1.4524	1.3680 to 1.5420	<0.0001
Stage (M1c vs others)	1.8326	1.5744 to 2.1331	<0.0001
Pretreatment (Yes vs No)	1.2472	1.0717 to 1.4515	0.0043
BRAF mutation (Yes vs No)	1.2444	1.0777 to 1.4369	0.0029
Age*	1.1392	1.0043 to 1.2922	0.0427
LMR*	0.6590	0.4800 to 0.9048	0.0099
AMC*	1.4994	1.1720 to 1.9182	0.0013
Therapy (ICI vs BRAFi/MEKi)	1.1396	0.9842 to 1.3196	0.0805
Gender (M vs F)	0.7749	0.6706 to 0.8953	0.0005

*Continuous variables, evaluated as contrast of the fourth versus the first quartile of the variable distribution.
AMC, absolute monocyte count; ANC, absolute neutrophil count; BRAFi, BRAF inhibitor; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; MEKi, MEK inhibitor; MIS, myeloid index score; NLR, neutrophil-to-lymphocyte ratio; WBC, white blood cells.